Introduction
Cardiovascular disease remains the leading cause of morbidity and premature mortality in the developed world, and myocardial infarction in particular confers a high risk of subsequent cardiac failure, arrhythmia and death. Since the introduction of ACE inhibitors into clinical practice in the early 1980s, we have discovered many of the mechanisms by which angiotensin II can be deleterious to the cardiovascular system. [1] [2] [3] In the setting of acute myocardial infarction, angiotensin II plays a significant detrimental role through augmentation of cardiac sympathetic outflow, reduced arterial compliance and impaired endothelial function. These factors contribute to cardiac remodelling, a process that predisposes to subsequent arrhythmia and cardiac failure. ACE inhibitor therapy in survivors of acute myocardial infarction reduces progression to severe cardiac failure and overall mortality, where the greatest benefits have been observed among patients with pre-existing impaired left ventricular systolic function. [4] [5] [6] Most clinical evidence of benefit in post-infarction patients has been obtained from studies of treatment initiated days to months after the primary infarction. Detrimental neurohormonal activation, including that of angiotensin II, is most prominent in the first hours and days after myocardial infarction, 7 but data supporting the use of ACE inhibitors in this period had been limited, leading to difficulty in determining the optimal time after infarction to initiate therapy. However, new clinical evidence is emerging that initiation of ACE inhibitor treatment within 24 hours of acute myocardial infarction significantly reduces mortality and the occurrence of cardiac failure. [8] [9] [10] [11] Therefore ACE inhibitor initiation within the first 24 hours provides a window of opportunity to save further lives among post-infarct patients, who are at particularly high risk during this period.
Cardiac remodelling
Important progressive changes in cardiac structure and function occur after myocardial infarction (collectively described as cardiac remodelling) which result in enlargement of the cardiac chambers and impairment of systolic efficiency. 12 Within the infarct zone collagen architecture is degraded and myocytes lose their normal tensile strength. 13 As a result of cell slippage, the infarct area stretches and becomes thin and enlarged, a process known as infarct expansion. 14 
Infarct
expansion predisposes to rupture and aneurysm formation, and is limited by the formation of a non-expansible fibrous scar towards the end of the first week. Myocardium surrounding the infarct becomes hypertrophied, and histological studies have shown early cellular changes remote from the infarct site within the first 24 hours. 15 Cardiac remodelling begins early after myocardial infarction even though the clinical consequences, especially cardiac failure and arrhythmia, may not be apparent until many years later.
Early systemic responses to myocardial infarction include activation of the sympathetic autonomic nervous system 16, 17 and the reninangiotensin-aldosterone axis. 7 Both of these have an early role in compensating for the acute reduction of cardiac output through direct cardiac inotropic effects and by increased end-diastolic filling pressure, respectively. However, activation of these reflexes also has an important influence on development of cardiac remodelling. Sympathetic cardiac influence increases heart rate and stroke volume and the resultant increased force of contraction promotes further cell slippage and infarct expansion. Activation of the renin-angiotensin-aldosterone system (RAAS) promotes fluid retention and increases cardiac preload. This may improve cardiac output but at the expense of increased wall tension, which increases infarct area expansion and stimulates hypertrophy of surrounding myocytes.Angiotensin II mediates important actions during myocardial infarction by direct stimulation of myocardial hypertrophy, facilitation of cardiac sympathetic activity and direct inotropic effects on the myocardium. Activation of the RAAS therefore plays a central role in the process of cardiac remodelling through a variety of haemodynamic and growth-stimulatory mechanisms. Remodelling is critically determined by the extent and site of the infarct, collateral cardiac function and the degree of neurohormonal activation.
Trials of ACE inhibitor treatment in patients with previous myocardial infarction
Experimental models of acute myocardial infarction show that ACE inhibitor treatment limits the extent of subsequent left ventricular dilatation and severity of systolic impairment. Captopril treatment significantly improves one-year survival after induction of myocardial infarction in rats; greatest survival benefit is evident in those animals with moderately extensive infarcts. 18 Early clinical trials in post-infarct patients who had radio-nuclide ejection fractions <0.45 showed that captopril significantly reduces the progression of ventricular dilatation and systolic impairment, leading to improved exercise tolerance. 19, 20 The early observations of haemodynamic improvement prompted several large clinical trials to assess the impact of ACE inhibitor therapy on long-term outcome measures and overall survival after myocardial infarction. Three landmark clinical studies of ACE inhibitor treatment in myocardial infarction patients significantly influenced their implementation in clinical practice, namely the Survival and Ventricular Enlargement (SAVE) study, 4 the Acute Infarction Ramipril Efficacy (AIRE) study 5 and the Trandolapril Cardiac Evaluation (TRACE) study. 6 The SAVE study 4, 21, 22 was the first published clinical trial of ACE inhibitor treatment in large numbers of patients who had suffered a myocardial infarction. 2231 patients with a confirmed myocardial infarction in the preceding 3-16 days and with left ventricular ejection fraction ≤0.40 were randomised to receive oral captopril up to 25 mg t.d.s. by forced dose titration, and up to 50 mg t.d.s. if indicated, in a double blind, placebocontrolled study. Mean ± SD follow-up period was 42 ± 10 months yielding a total 7808 patient study years. The placebo-treated group had an overall mortality of 25% (275 of 1116) compared with 20% (228 of 1115) in the group receiving captopril, a relative mortality reduction of 19% (95% CI 3-32%, p=0.019). Hospitalisation for severe cardiac failure occurred in 17% of the placebo-treated group (192 of 1116) and 14% of the captopriltreated group (154 of 1115), a 22% risk reduction (95% CI 4-37%, p=0.019).The SAVE study showed unequivocally that treatment of post-infarct patients with an ACE inhibitor could lead to a substantial reduction in cardiovascular risk and improved long-term survival.A significant proportion of the study population had received additional treatment including aspirin (59%), thrombolytic treatment (33%) and beta-blockade (35%), and although the absolute cardiovascular morbidity and mortality was lower in patients who had received additional therapy, captopril treatment resulted in a further significant risk reduction.The relative risk reduction was similar regardless of other secondary prevention treatment, indicating that the benefits of ACE inhibitor therapy in postinfarct patients are additional to those from other treatments.
In the AIRE 5,23 study, 2004 patients with clinical and/or radiological evidence of left ventricular failure were recruited 3-10 days after definite myocardial infarction, and randomised to receive either placebo or ramipril 2.5 mg b.d., escalated to 5 mg b.d. after two days if tolerated. The mean study period was 15 months resulting in 2507 total patient years of follow-up. Overall mortality in the placebo-treated group was 23% (222 of 982) and 17% in the ramipril-treated group (170 of 1004), representing a 27% relative risk reduction (CI 11-40%, p=0.002). Severe heart failure occurred in 18% of those assigned to placebo (178 of 982) and 14% of those treated with ramipril (143 of 1004), a relative risk reduction of 21%. Patients who had received additional aspirin (78%), thrombolytic treatment (58%) or betablockade (22%) gained a further reduction of cardiovascular risk from the addition of ACE inhibitor therapy, as in the SAVE study.The AIRE study confirmed the substantial benefits of ACE inhibitor treatment to post-myocardial infarction patients, and showed that high-risk patients selected on the basis of clinical and/or radiological criteria gain a substantial mortality reduction.
In the TRACE 6,24 study, 1749 patients were recruited, having had a confirmed myocardial infarction and an echographic wall motion index ≤ 0.12 (equivalent to ejection fraction ≤ 0.35). Treatment commenced 3-7 days after infarction and patients were randomly allocated to receive either placebo or trandolapril, initially 1 mg daily and increased to 4 mg daily over four weeks, if tolerated. Mean follow-up in this group was 26.5 months with a consequent 3862 total patient years of follow-up. This was a high-risk selected population with all-cause mortality of 42.3% in the placebo-treated group (369 of 873).The mortality rate in trandolapril-treated patients was 34.7% (304 of 876), representing a 22% relative mortality reduction (95% CI 9-33%, p=0.001). Among patients who had received aspirin (91%), thrombolytic therapy (45%) and beta-blockade (16%), trandolapril led to a similar relative mortality reduction. Severe cardiac failure occurred in 20% of the placebo group (171 of 873) compared with 14% of the trandolapril-treated group (125 of 876), a 29% relative risk reduction (95% CI 11-44%, p=0.003). Thus, high-risk post-infarct patients, selected on the basis of echographic severe left ventricular systolic impairment, gain substantial benefits from ACE inhibitor therapy, and as in the SAVE and AIRE studies, these benefits are additional to those of other secondary prevention measures.
Early pre-clinical and clinical data indicate beneficial haemodynamic effects of ACE inhibitors after acute myocardial infarction. The SAVE, AIRE and TRACE landmark studies provided unequivocal evidence that ACE inhibitors improve longterm outcome and survival following myocardial infarction. Meta-analysis from these three trials show mortality occurring in 29% (866 of 2971) of patients receiving placebo compared with 23% (702 of 2995) of those receiving ACE inhibitor treatment, a combined relative mortality reduction of 26% (95% CI 17-34%, p<0.005).The pathophysiological mechanisms which underlie the benefits of ACE inhibitor treatment result from reduction in left ventricular remodelling and reduction in sympathetic cardiac influence, reflected in the reduction of sudden cardiac deaths (TRACE).
Trials of early ACE inhibitor treatment after myocardial infarction
The process of ventricular remodelling begins EDITORIAL REVIEW early, and activation of the RAAS occurs within the first few hours or days following acute myocardial infarction. 9 ACE inhibitor therapy in the SAVE, AIRE and TRACE studies was not initiated until at least several days after the index myocardial infarction; 11 (3-6) days, 5.4 (2-10) days and 4.5 (3-7) days respectively (mean and range). Any benefit in the early post-infarction period would have been overlooked, and a number of subsequent clinical trials have been conducted to study the effect of treatment within the first 24 hours. The Cooperative New Scandanavian Enalapril Survival Study II (CONSENSUS II), 25 the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarcto Miocardio (GISSI) 3 study, 8 the Fourth International Study of Infarct Survival (ISIS-4) 9 and the Survival of Myocardial Infarction Long-term Evaluation (SMILE) study 10 are all large, randomised trials examining the effects of initiating ACE inhibitor treatment within 24 hours of myocardial infarction onset.
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The CONSENSUS II trial 25 was a multicentre study of 6090 post-infarction patients, not selected on the basis of left ventricular function, who had systolic blood pressure of at least 100 mmHg at entry. Patients were randomised to receive very early treatment with placebo or intravenous enalaprilat (the active metabolite of enalapril) followed by oral enalapril. 1 mg enalaprilat was administered intravenously over two hours. The infusion was stopped if systolic or diastolic BP fell below 90 and 60 mmHg respectively and could be recommenced at the discretion of the responsible physician. Oral enalapril, 2.5 mg was administered six hours later followed by 2.5 mg b.d. on day two, 5 mg b.d. on day three, 10 mg once on day four and 20 mg once daily thereafter, titration occurring only if systolic and diastolic blood pressures were at least 100 and 60 mmHg respectively. Eight months after patient recruitment began, the safety monitoring committee indicated a non-significant trend towards increased mortality among elderly patients with severe hypotension. The protocol was amended such that systolic blood pressure should be at least 105 mmHg at entry, the duration of enalaprilat infusion increased to three hours, and if systolic blood pressure fell below 100 mmHg then the infusion was terminated. After several further months, the study was discontinued early at the request of the safety committee. Follow-up ranged between 41 and 180 days, and 2592 patients were followed up for 180 days. Other secondary prevention therapy had been administered, including aspirin (85%), thrombolytic drugs (56%) and beta-blocker therapy (66%). Overall mortality was 9.4% in those receiving placebo (286 of 3046), while those patients who had received enalapril had overall mortality of 10.2% (312 of 3044) representing a non-significant mortality increase of 10% (95% CI -29-7%, p=0.26). Of those receiving placebo, 30% (908 of 3046) required a change of therapy because of heart failure compared with 27% (810 of 3044) of the enalapril group, and there was a non-significant trend towards reduced hospitalisation for heart failure among patients who had received enalapril 4% (130 of 3044) compared with placebo 6% (176 of 3046). While strictly speaking the null hypothesis applies to the CONSENSUS II study, the trend towards increased mortality raised important safety concerns about the early administration of ACE inhibitor treatment after myocardial infarction. The excess mortality appeared to be related to the occurrence of severe hypotension and first dose hypotension. Average trough blood pressure was 117/72 mmHg among those receiving placebo compared with 109/66 mmHg for those receiving enalapril, and the occurrence of symptomatic first dose hypotension was 2% and 7% respectively. Occurrence of systolic or diastolic blood pressure lower than 90 mmHg and 50 mmHg respectively was 3% in the placebo group compared with 12% in the enalapril group (p<0.001). Patients over 70 years of age who received placebo had a mortality rate of 14.7% compared with 17.3% among those receiving enalapril, although the trend towards increased mortality in this age group was not statistically significant (p=0.07). Mortality rates were similar across predefined subgroups including concomitant diabetes, hypertension, and previous myocardial infarction and those taking cardio-active medication.
The GISSI-3 study 8, 26 was a large, multi-factorial, placebo-controlled trial investigating the effects of lisinopril and/or nitrate therapy administered within 24 hours of onset of chest pain to patients with confirmed acute myocardial infarction. As in the CONSENSUS II study, patients were not selected on the basis of left ventricular systolic impairment, and systolic blood pressure was at least 100 mmHg at entry. Complete data were available for 18,895 of the 19,394 patients randomised to receive either lisinopril (9435) or matched placebo (9460). Lisinopril was initiated as 5 mg daily and increased after two days, if tolerated, to 10 mg daily and continued for six weeks. If systolic blood pressure fell below 100 mmHg, then the dosage could be reduced to 5 or 2.5 mg daily. Patients had received additional treatment with aspirin (84%), thrombolytic treatment (72%) and intravenous beta-blockade (31%). At the end of the six-week treatment period, overall mortality was 7.1% (673 of 9460) in the control group compared with 6.3% (597 of 9435) in the lisinopril group, a relative mortality reduction of 12% (95% CI 1-21%, p=0.015). Clinical heart failure occurred in 3.7% (354 of 9460) receiving placebo and 3.9% (366 of 9435) receiving lisinopril, which was not significantly different. As in the CONSENSUS II study, GISSI-3 found that early ACE inhibitor treatment of myocardial infarction patients substantially increased the occurrence of severe hypotension, and that this contributed to mortality among patients receiving lisinopril. Persistent hypotension (systolic blood pressure less than 90 mmHg sustained for at least one hour) occurred in 3.7% (351 of 9460) of the control group compared with 9.0% (852 of 9435) of those receiving lisinopril, a relative increase of 144% (95% CI 117-174%).
There were 145 deaths among lisinopril-treated patients who developed severe hypotension (24% of all deaths in this group) compared with 102 in the control group (15% of all control group deaths). Withdrawal of lisinopril treatment due to severe hypotension occurred in 9.7% of patients by the end of the six-week treatment period.The GISSI-3 study showed that early ACE inhibitor initiation and short-term treatment after myocardial infarction is safe and significantly reduces early mortality. It also identified the importance of severe hypotension, an adverse effect which could potentially limit the value of early treatment.
ISIS-4 9, 27 was a multifactorial study of the effects of early administration of captopril and/or nitrate and/or magnesium to unselected myocardial infarction patients. 58,050 patients were randomised to receive treatment with placebo or captopril (initiated as 6.25 mg and followed by 12.5 mg two hours later, 25 mg 10-12 hours later and then 50 mg b.d. for four weeks). Systolic blood pressure at entry was at least 90 mmHg, and patients had received other treatments including antiplatelet therapy (93%), thrombolytic treatment (68%) and intravenous beta-blockade (9%). Trial medication could be reduced or stopped if severe hypotension developed. Overall mortality at five weeks was 7.69% (2231 of 29,022) in the control group and 7.19% (2088 of 29,028) in the captopril group, representing a 7% relative mortality reduction (95% CI 1-13%, p=0.02).This effect persisted for at least one year after myocardial infarction even though treatment was administered for only four weeks. Cardiac failure occurred in 17.3% (4952 of 29,022) of the placebo group during the treatment period and 17.0% (4847 of 29,028) of the captopril group, which was not significantly different. Profound hypotension occurred in 11.0% of those receiving placebo (3130 of 29,022) and in 20.9% of those receiving captopril (5951 of 29,028), p<0.00005. Cardiogenic shock and hypotension severe enough to require study termination occurred in 4.1 and 4.8% of those receiving placebo (1170 and 1368 of 29,022) compared with 4.6 and 10.0% of those receiving captopril (1309 and 2851 of 29,028), p<0.005 and p<0.00005 respectively.The number of confirmed myocardial infarctions amongst the captopril-treated group was significantly higher than the control group (92.3% compared with 91.8%, p<0.05), which may reflect the contribution of severe hypotension to global myocardial ischaemia, although this may have simply been a chance finding. Despite the occurrence of early hypotension, the ISIS-4 study supported the findings from the GISSI group that very early ACE inhibitor intervention significantly improves survival after myocardial infarction, in patients not selected on the basis of left ventricular systolic dysfunction.
The SMILE 10,28 study was a prospective multicentre study of 1556 patients who had sustained a confirmed anterior wall myocardial infarction, and who had been ineligible to receive thrombolysis treatment. Other treatment at study entry included antiplatelet therapy (54%) and beta-blockers (20%). On the basis of the chosen selection criteria, this cohort were thought to be at high risk of left ventricular systolic dysfunction, although this was not a specific selection criterion. Patients were randomised to receive placebo or oral zofenopril, initiated as 7.5 mg with a further 7.5 mg dosage after twelve hours and progressive dose titration towards a target of 30 mg b.d., if systolic blood pressure remained above 100 mmHg and there were no signs or symptoms due to hypotension. Treatment commenced within 24 hours of symptom onset and continued for six weeks. At the end of the treatment period, 75.5% of the placebo group (592 of 784) and 75.1% of the zofenopril group (580 of 772) were taking their assigned study medication, with 86.1% and 78.8% achieving the 60 mg target dose respectively. The predetermined end-point of the study was death or severe cardiac failure requiring open label ACE inhibitor treatment. This end-point was reached in 10.6% (83 of 784) patients in the placebo group and 7.1% (55 of 772) patients receiving zofenopril, representing a risk reduction of 34% (95% CI 8-54%, p=0.018). Overall mortality in the placebo group was 8.3% (65 of 784) at the end of the treatment period compared with 6.5% (50 of 772) in the zofenopril group, a non-significant mortality reduction of 25% (95% CI -11-60%, p=0. 19) . At one year, mortality in the placebo group was 14.1% (111 of 784) compared with 10.0% (77 of 772) in the zofenopril group, representing a 29% annual mortality reduction (95% CI 6-51, p=0.011). Severe cardiac failure, necessitating open-label ACE inhibitor treatment occurred in 4.1% (32 of 784) of the placebo group compared with 2.2% (17 of 772) in the zofenopril group, a 46% risk reduction (95% CI 11-71%, p=0.018). In contrast to CONSENSUS II, GISSI-3 and ISIS-4 studies, patients randomised to receive zofenopril in the SMILE study experienced much fewer episodes of severe hypotension. Severe first dose hypotension occurred in 0.3 and 0.6% of patients treated with placebo and zofenopril respectively, while treatment discontinuation due to symptomatic or severe hypotension (systolic blood pressure lower than 90 mmHg) occurred in 2.7 and 3.8% respectively. The SMILE study showed that the benefits of early ACE inhibitor intervention extend to myocardial infarction patients who are at high-risk on the basis of simple clinical criteria.As with the ISIS-4 study, shortterm early intervention resulted in improved clinical outcome, which was found to persist for at least one year after myocardial infarction.
From clinical studies to clinical practice
The SAVE,AIRE and TRACE studies clearly indicate that ACE inhibitor treatment substantially reduces cardiovascular risk in patients with previous myocardial infarction who have clinical, radiological or echocardiographic evidence of impaired left ventricular systolic function.The benefits of treatment appear to be sustained by prolonged treatment, consistent with evidence of improved out- EDITORIAL REVIEW come in long-term trials of ACE inhibitor treatment in patients with chronic congestive cardiac failure. 29 These studies also suggest that late initiation and continued ACE inhibitor treatment is of greatest benefit in post-infarct patients who have impaired left ventricular systolic function. Therefore, investigation of post-infarct patients by echocardiography or ventriculography is necessary to identify those patients most likely to experience greatest long-term benefits, because patients with an ejection fraction of <0.40 have no clinical or radiological signs of heart failure in 36% and 67% respectively. 30 ACE inhibitor treatment of unselected patients in GISSI-3 and ISIS-4 studies showed greatest benefit in those with significantly impaired left ventricular systolic function. In GISSI-3, mortality among patients receiving placebo or lisinopril with Killip class I at randomisation was 5.3 and 5.0% (6% relative reduction, NS) and for those with Killip class II or higher mortality was 17.4% and 14.4% (20% relative reduction, p=0.03). 8 The ISIS-4 study showed that captopril reduced overall mortality by 5% from 6.3% (1586 of 24,980) to 6.0% (1502 of 24,997) in those with no heart failure at baseline compared to a 9% reduction from 16.0% (645 of 4041) to 14.5% (585 of 4029) in those with heart failure at baseline. 9 Although greatest benefits were seen in patients with impaired baseline left ventricular systolic function, these studies also suggest that patients with preserved ventricular function gain a significant, albeit smaller, benefit. The beneficial early effects of ACE inhibitor treatment may be due to early additional anti-ischaemic or anti-arrhythmic effects in addition to more prolonged effects on left ventricular remodelling.
The GISSI-3, ISIS-4 and SMILE studies strongly support the initiation of ACE inhibitor treatment within the first 24 hours of myocardial infarction. This is further supported by findings of the Chinese Cardiac Study (CCS-1) Collaborative Group who conducted a randomised study of four weeks treatment with placebo or captopril initiat-ed within 36 hours of confirmed acute myocardial infarction in 14,962 unselected patients. 11, 31 Captopril was associated with a non-significant reduction in four-week mortality (9.12% compared with 9.74%, p=0.20) and led to a significant reduction in the occurrence of heart failure (17.0% compared with 18.7%, p=0.01). Although the CONSENSUS II study did not directly support early treatment, its findings were not statistically inconsistent with a meta-analysis of trials of early ACE inhibitor initiation, indicating that treatment led to an added 4.6 survivors per 1000 myocardial infarction patients treated (p=0.006). 32 This analysis included data from smaller randomised controlled trials, CONSENSUS II, GISSI-3, ISIS-4 and interim data from the CCS-1 study, but did not include SMILE data. Inclusion of SMILE data results in a similar overall survival benefit (Table 1) .
A significant proportion of the mortality reduction gained in GISSI-3, ISIS-4, SMILE and CCS-1 is gained early, with a substantial impact within the first 24 hours ( Table 2 ). Early initiation of ACE inhibitor treatment leads to substantial immediate improvements in outcome, with about two lives saved per thousand patients treated in the first 24 hours alone. These benefits have been shown in patients unselected on the basis of left ventricular systolic impairment, indicating that early ACE inhibitor treatment should be considered appropriate for all patients presenting with acute myocardial infarction.
An important adverse effect of early ACE inhibitor initiation in post-infarct patients is the development of severe hypotension. This was probably the main factor that confounded any potential benefits of enalapril in the CONSENSUS II study, and contributed to withdrawal of lisinopril in large numbers of patients in the GISSI-3 study, as discussed above. Severe hypotension occurred more commonly in patients with lower baseline systolic blood pressure, and this was predictive of poor outcome in the ISIS-4 study. Overall mortality rates for placebo-and lisinopril-treated patients were 7.6 and 7.0% if baseline systolic blood pressure was at least 100 mmHg, compared to 12.4 and 14.2% in patients with baseline systolic blood pressure less than 100 mmHg. 8 Interestingly, the absolute mortality reduction from zofenopril in SMILE was substantially greater than that of lisinopril or captopril in GISSI-3 and ISIS-4. This may, in part, be due to the patients entered in SMILE who were at high risk of left ventricular systolic dysfunction. This is consistent with subgroup analysis of patients with anterior wall infarction in the CCS-1 study who gained a significant mortality reduction from captopril treatment (10.2% compared with 8.6%, p=0.02) despite no significant mortality reduction in the overall group. 11 Alternatively, the high absolute mortality reduction in SMILE may reflect the lower incidence of severe hypotension, and greater proportion of patients treated due to higher tolerability than enalapril, lisinopril and captopril in the CONSENSUS II, GISSI-3 or ISIS-4 studies respectively ( Table 3 ). The high incidence of severe hypotension in these studies may have been exaggerated by reperfusion injury associated with thrombolytic treatment, not administered to patients participating in the SMILE study. Alternatively, beneficial ancillary properties of zofenopril, such as high selectivity of myocardial tissue uptake, 33 may have made an important contribution to the favourable blood pressure profile found in SMILE. This may become clearer when the results of SMILE-2 are available; this is a randomised, double-blind outcome study of early intervention with zofenopril or lisinopril after myocardial infarction in patients eligible to receive thrombolytic and other secondary prevention treatment.
Conclusions
There is a wealth of evidence supporting the use of ACE inhibitors in patients who have suffered a previous myocardial infarction and who have evidence of impaired left ventricular systolic dysfunction, in the presence or absence of clinically overt cardiac failure. The slowed progression of deteriorating cardiac performance and improved survival are closely associated with attenuation of cardiac remodelling, and this benefit is likely to continue with long-term treatment. Over recent years, substantial evidence has now accrued in favour of initiation of ACE inhibitor treatment within 24 hours to unselected myocardial infarction patients. A lower incidence of cardiac failure and improved survival are evident even within the first 24 hours, and the benefits of short-term early treatment persist for up to at least one year after myocardial infarction. Early treatment is associated with more frequent severe hypotension, necessitating careful patient selection and monitoring during treatment. Mechanisms underlying the benefits of very early treatment are probably related to attenuation of sympathetic nervous activity and/or anti-ischaemic effects, and there is no clear evidence advocating continued ACE inhibitor treatment beyond four to six weeks in patients with preserved left ventricular systolic function. Early initiation of ACE inhibitor treatment within 24 hours of myocardial infarction provides the opportunity to save lives, even in addition to other secondary prevention including aspirin, thrombolytic treatment and beta-blockade. Early initiation of ACE inhibitor treatment is an essential part of clinical care that should be delivered to all patients after myocardial infarction, to achieve maximal reduction of morbidity and mortality in this high-risk period.
